MariTide Enters Phase 3, GLP-1 Neurological Repositioning Advances, Semaglutide Outperforms Tirzepatide on CV Outcomes, and GLP1R Pharmacogenomics Breakthrough: April 27, 2026

MariTide (Maridebart Cafraglutide) Advances into Phase 3 MARITIME Program

Amgen's maridebart cafraglutide — branded MariTide — has entered the phase 3 MARITIME clinical program following phase 2 results published in the New England Journal of Medicine showing up to 20% mean weight loss at 52 weeks in adults with obesity and no weight-loss plateau. MariTide is mechanistically unique among incretin-based obesity therapies: it combines GIP receptor antagonism with GLP-1 receptor agonism in a single antibody-peptide conjugate molecule dosed once monthly. This stands in direct contrast to tirzepatide, which activates both GIP and GLP-1 receptors. The debate over whether blocking or activating GIP produces better long-term metabolic outcomes is now one of the most closely watched questions in obesity pharmacology. In participants with type 2 diabetes, MariTide produced up to 17% weight loss with HbA1c reductions of 2.2 percentage points. The MARITIME program includes MARITIME-1 (obesity/overweight, 72 weeks), MARITIME-2 (T2D with obesity), and additional studies targeting cardiovascular disease, heart failure, chronic kidney disease, and obstructive sleep apnea. Phase 3 results are expected in 2027–2028. MariTide's once-monthly dosing schedule represents a meaningful adherence advantage over weekly injectables, and Amgen has signaled manufacturing scale-up investment to meet anticipated demand.

GLP-1 Drugs Being Repositioned for Alzheimer's and Parkinson's Disease

An April 2026 review in NeurologyLive synthesized growing evidence that GLP-1 receptor agonists — originally developed for diabetes and obesity — may have significant neuroprotective potential. Semaglutide is now being evaluated in clinical trials for Alzheimer's disease and Parkinson's disease, building on preclinical data showing reduced neuroinflammation, improved cerebral glucose metabolism, decreased amyloid-beta accumulation, and enhanced synaptic plasticity in rodent models. The mechanistic rationale centers on the observation that GLP-1 receptors are expressed throughout the central nervous system, particularly in the hippocampus and substantia nigra — regions affected earliest in Alzheimer's and Parkinson's respectively. Epidemiological studies have found that patients taking GLP-1 agonists for diabetes show lower rates of neurodegenerative disease diagnosis, though confounding factors make causal inference difficult. Nature Medicine's 2026 review of the expanding GLP-1 landscape positioned neurological applications as the next frontier after cardiovascular, renal, and hepatic indications. If ongoing trials confirm neuroprotective efficacy, GLP-1 agonists could become one of the most broadly prescribed drug classes in medicine, with applications spanning metabolic, cardiovascular, hepatic, renal, and neurological disease.

STEER Analysis: Semaglutide Shows 57% Greater Cardiovascular Risk Reduction vs Tirzepatide

A large retrospective analysis called STEER, examining adults with overweight or obesity and established cardiovascular disease, found that semaglutide 2.4 mg demonstrated a 57% greater reduction in major adverse cardiovascular events (MACE) compared with tirzepatide. While this is observational data with inherent limitations — including potential selection bias and differences in baseline risk profiles — it represents the first large-scale head-to-head cardiovascular comparison between the two dominant GLP-1 class agents. The finding is particularly notable because tirzepatide's dual GIP/GLP-1 mechanism was hypothesized to provide at least equivalent cardiovascular protection. Several explanations have been proposed: semaglutide has longer post-marketing cardiovascular safety data (SELECT trial), and the GLP-1 receptor may mediate cardiovascular benefits more directly than the GIP receptor. Randomized controlled trials directly comparing the two drugs on cardiovascular endpoints are not yet underway, so the STEER results should be interpreted as hypothesis-generating rather than definitive. Clinicians and researchers are watching for the AHA's response and whether this data influences treatment algorithm positioning.

GLP1R Pharmacogenomics: A Nature GWAS Identifies Variants Predicting Weight Loss Response

A landmark genome-wide association study (GWAS) published in Nature in April 2026 identified a missense variant in the GLP1R gene that significantly associates with differential BMI loss in response to both semaglutide and tirzepatide. Carriers of the variant showed measurably different weight loss trajectories and side effect profiles compared to non-carriers, providing the first robust pharmacogenomic predictor for GLP-1 agonist response. This research has immediate implications for personalized prescribing: patients who are poor responders to one GLP-1 agent based on their GLP1R genotype might benefit from agents with different receptor profiles (such as triple agonists like retatrutide or GIP antagonists like MariTide). The study also found that specific GLP1R variants correlated with gastrointestinal side effect severity, potentially allowing clinicians to predict and mitigate tolerability issues before treatment initiation. While clinical implementation of pharmacogenomic testing for GLP-1 prescribing is not yet standard practice, several academic medical centers have begun pilot programs incorporating GLP1R genotyping into obesity treatment algorithms.

Pipeline Snapshot: Where the Obesity Peptide Race Stands in Late April 2026

The obesity peptide pipeline is now the most crowded and competitive in pharmaceutical history. Here is where the major contenders stand as of April 27, 2026. Semaglutide (Novo Nordisk) remains the market leader with oral 25mg Wegovy tablets available since January 2026 and accelerated FDA approval for MASH liver disease. Tirzepatide (Eli Lilly) continues expanding indications with positive SURMOUNT-OSA data for obstructive sleep apnea and ongoing cardiovascular outcome trials. Retatrutide (Eli Lilly) is the first triple agonist (GLP-1/GIP/glucagon) in advanced clinical development, with TRIUMPH-1 phase 3 obesity results expected H2 2026 — phase 2 data showed 24.2% weight loss at 48 weeks. CagriSema (Novo Nordisk) combines cagrilintide and semaglutide, with an NDA submitted December 2025 following 20.4% weight loss in REDEFINE-1 and positive REIMAGINE-2 results in April 2026. Survodutide (Boehringer Ingelheim/Zealand) is a dual glucagon/GLP-1 agonist in phase 3 SYNCHRONIZE trials. MariTide (Amgen) is the sole GIP antagonist/GLP-1 agonist, now in phase 3 with up to 20% weight loss and monthly dosing. Orforglipron (Eli Lilly) became the first oral non-peptide GLP-1 agonist to receive FDA approval in April 2026, marking a paradigm shift toward pill-based obesity treatment. The International Journal of Obesity published new data in 2026 comparing efficacy of these agents in MC4R-deficient obesity models, finding that triple agonism and alternative receptor profiles may overcome genetic resistance to single-target GLP-1 therapy.

Citations

1. [1] Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity — A Phase 2 Trial. NEJM 2026 Source
2. [2] Inside Amgen's Phase 3 MARITIME Program — Amgen, June 2025 Source
3. [3] Repositioning GLP-1 Drugs for Neurologic Disease: Evidence, Advances, and Outlook — NeurologyLive, April 2026 Source
4. [4] APhA2026: GLP-1 Therapies Are Rewriting the Rules of Metabolic Disease — Pharmacy Times Source
5. [5] The expanding landscape of GLP-1 medicines — Nature Medicine 2026 Source
6. [6] Genetic predictors of GLP1 receptor agonist weight loss and side effects — Nature 2026 Source
7. [7] Efficacy of GLP-1 analog peptides on MC4R deficient obesity — International Journal of Obesity 2026 Source
8. [8] GLP-1 Not Needed for Weight Loss? GIP/Glucagon Insights 2026 — The Peptide Catalog Source
9. [9] ClinicalTrials.gov — MARITIME-1 Study (NCT06858878) Source